Celldex Therapeutics (NASDAQ:CLDX) Rating Reiterated by Wolfe Research
Wolfe Research restated their outperform rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research note released on Wednesday, MarketBeat Ratings reports. The brokerage currently has a $51.00 price target on the biopharmaceutical company’s stock. A number of other equities analysts also recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an overweight […]
29 Sep 07:13 · The Markets Daily